Stockreport

Oyster Point Pharma’s OC-01 Nasal Spray Meets Primary Endpoint in Phase 2 Mystic Trial in Subjects With Dry Eye Disease

Oyster Point Pharma, Inc. - common stock  (OYST) 
Last oyster point pharma, inc. - common stock earnings: 2/27 04:01 pm Check Earnings Report
PDF OC-01 nasal spray showed a statistically significant improvement in Schirmer’s score at Day 84 in both doses tested compared to control  OC-01 nasal spray is a preservat [Read more]